I have been wondering the overall impact of the Zenith/RVX epigenetics drugs, on their own as standalones. They may be better overall in combination, but I have been curious whatever the impact with epigenetics as the sole MOA, and if there is a value for standalone vs combinations, in various specific types of patients, especially given safety record and lack of side effects.

Guessing/assuming this has already been vetted and calculated within the Zenith/RVX science teams with industry clinical guidance on "probabilities" since combinations (especially RVX) has been the target and rule, so far? Plus, maybe, it is a good way to show wealthy strategic forward looking BP's how much extra benefit epigenetics can bring to their existing R&D platforms, for future efficacy considerations, combo patent extensions, etc?? Dressing up somebody else's baby?

Anyway, continued good luck and good sailing for Zenith!